HEALTH● LOWJun 29 · Jun 29, 2026, 10:14 PM
Praxis sees encephalopathies asset relutrigine action date extended
Seeking Alpha Tech
Praxis has seen the action date for its encephalopathies asset, relutrigine, extended. This indicates a change in the regulatory timeline for the drug.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH28m agoLost your spark? The "silent sister" of depression, and a quiz to spot herNPR NewsHEALTH58m agoEbola: Africa CDC warns continent ‘not winning’ as cases surpass 10,000Premium TimesHEALTH1h ago‘One in 4 Nigerian stroke patients under 50’Vanguard NigeriaHEALTH1h agoThe national government issued a list of recommendations to prevent and detect a dangerous avian disease after an outbreak in BrazilClarín